| Scrip Code | 543213 |
|---|---|
| NSE Symbol | ROSSARI |
| MSEI Symbol | NOTLISTED |
| ISIN | INE02A801020 |
| Name of company | ROSSARI BIOTECH LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 27-04-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 18-04-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Fourth quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Audited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Audited |
| Segment Reporting | Single segment |
| Description of single segment | Manufacturing of Specialty Chemicals for Textile, Home and Personal Care, Performance Chemicals and Animal Health and Nutrition industries |
| Start date and time of board meeting | 27-04-2026 14:00:00 |
| End date and time of board meeting | 27-04-2026 15:45:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Whether the company has any related party? | Yes |
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | Yes |
| (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public | NA |
| (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. | NA |
| Whether the company is a high value debt listed entity according to regulation 15 (1A)? | No |
| (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? | |
| (b) If answer to above question is No, please explain the reason for not complying. | |
| Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? | Yes |
| Latest Date on which RPT policy is updated | 27-04-2026 |
| Indicate Company website link for updated RPT policy of the Company | www.rossari.com/corporate-governance |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | No |
| No. of times funds raised during the quarter | |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | Yes |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 51,613.80 | 1,75,206.60 | |
| Other income | 2,272.90 | 2,700.90 | |
| Total income | 53,886.70 | 1,77,907.50 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 32,889.00 | 1,06,642.50 |
| (b) | Purchases of stock-in-trade | 5,804.30 | 23,846.30 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 425.10 | 193.10 |
| (d) | Employee benefit expense | 1,775.20 | 6,946.20 |
| (e) | Finance costs | 381.00 | 1,334.90 |
| (f) | Depreciation, depletion and amortisation expense | 897.10 | 3,093.30 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 4,360.40 | 16,745.00 |
| Total other expenses | 4,360.40 | 16,745.00 | |
| Total expenses | 46,532.10 | 1,58,801.30 | |
| 3 | Total profit before exceptional items and tax | 7,354.60 | 19,106.20 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 7,354.60 | 19,106.20 |
| 6 | Tax expense | ||
| 7 | Current tax | 1,350.80 | 4,490.50 |
| 8 | Deferred tax | 530.80 | 331.90 |
| 9 | Total tax expenses | 1,881.60 | 4,822.40 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 5,473.00 | 14,283.80 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 5,473.00 | 14,283.80 |
| 17 | Other comprehensive income net of taxes | 16.10 | (5.00) |
| 18 | Total Comprehensive Income for the period | 5,489.10 | 14,278.80 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 1,107.70 | 1,107.70 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | 0.00 | |
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 9.88 | 25.79 | |
| Diluted earnings (loss) per share from continuing operations | 9.88 | 25.78 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 9.88 | 25.79 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 9.88 | 25.78 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | Notes:1.The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 27th April, 2026.2.The standalone financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS), as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.3. The Company deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Company considers it as one operating segment.4.During the quarter ended 31st March, 2026, the Company has allotted 2,000 equity shares of Rs. 2 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.5.The figures for the quarter ended 31st March, 2026 and 31st March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.6.During the quarter ended 31st March, 2026, the Company has sold its Kanjurmarg Office for a consideration of Rs. 250 million. Consequently, the Company has recognised a gain of Rs. 192.67 million (net) under the head ‘Other Income’ in the Statement of Profit and Loss.7.The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz., Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (Collectively referred to as the ‘New Labour Codes’). These codes have been made effective from 21st November, 2025.The Company has estimated the revised gratuity liability as at 31st December 2025 and as at 31st March 2026 as per the New Labour Codes and the additional liability arising thereon has been recognized as part of employee benefit expenses in the current reporting period. No material additional liability on compensated absences and provident fund arose on account of the aforesaid codes. The Government is in the process of notifying related rules to the New Labour Codes and impact of these will be evaluated and accounted for in accordance with applicable accounting standards in the period in which they are notified.8.The Board of Directors have recommended final dividend of Re.0.50 (25 percent of the face value of the equity share of Rs. 2 each) for the financial year ended 31st March,2026.9.Previous year / period figures have been regrouped to make them comparable with the current year / period figures, wherever applicable, which are not material. For ROSSARI BIOTECH LIMITED EDWARD MENEZES Executive Chairman DIN:00149205 Place:Mumbai Date:27 April, 2026 |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | Year ended (dd-mm-yyyy) | |
|---|---|---|
| Date of start of reporting period | 01-04-2025 | |
| Date of end of reporting period | 31-03-2026 | |
| Whether results are audited or unaudited | Audited | |
| Nature of report standalone or consolidated | Standalone | |
| Assets | ||
| 1 | Non-current assets | |
| Property, plant and equipment | 21,116.60 | |
| Capital work-in-progress | 10,498.90 | |
| Investment property | ||
| Goodwill | 106.00 | |
| Other intangible assets | 539.90 | |
| Intangible assets under development | ||
| Biological assets other than bearer plants | ||
| Investments accounted for using equity method | ||
| Non-current financial assets | ||
| Non-current investments | 51,250.80 | |
| Trade receivables, non-current | ||
| Loans, non-current | 0.00 | |
| Other non-current financial assets | ||
| 1 | Other Financial Assets | 334.00 |
| Total of other non-current financial assets | 334.00 | |
| Total non-current financial assets | 51,584.80 | |
| Deferred tax assets (net) | 331.50 | |
| Other non-current assets | ||
| 1 | Income Tax Assets (Net) | 496.30 |
| 2 | Other non-current assets | 1,389.50 |
| Total of other non-current assets | 1,885.80 | |
| Total non-current assets | 86,063.50 | |
| 2 | Current assets | |
| Inventories | 17,972.70 | |
| Current financial asset | ||
| Current investments | 3,510.00 | |
| Trade receivables, current | 51,843.00 | |
| Cash and cash equivalents | 4,864.80 | |
| Bank balance other than cash and cash equivalents | 320.60 | |
| Loans, current | 4,037.60 | |
| Other current financial assets | ||
| Total of other current financial assets | 3,772.50 | |
| Total current financial assets | 68,348.50 | |
| Current tax assets (net) | ||
| Other current assets | ||
| 1 | Other current assets | 3,978.90 |
| Total of other current assets | 3,978.90 | |
| Total current assets | 90,300.10 | |
| 3 | Non-current assets classified as held for sale | 0.00 |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | 0.00 |
| Total assets | 1,76,363.60 | |
| Equity and liabilities | ||
| 1 | Equity | |
| Equity attributable to owners of parent | ||
| Equity share capital | 1,107.70 | |
| Other equity | 1,20,741.70 | |
| Total equity attributable to owners of parent | 1,21,849.40 | |
| Non controlling interest | ||
| Total equity | 1,21,849.40 | |
| 2 | Liabilities | |
| Non-current liabilities | ||
| Non-current financial liabilities | ||
| Borrowings, non-current | 512.40 | |
| Trade payables, non-current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | 0.00 | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 0.00 | |
| Total Trade payable | 0.00 | |
| Other non-current financial liabilities | ||
| 1 | Lease Liabilities | 1,358.40 |
| Total of other non-current financial liabilities | 1,358.40 | |
| Total non-current financial liabilities | 1,870.80 | |
| Provisions, non-current | 524.00 | |
| Deferred tax liabilities (net) | 0.00 | |
| Deferred government grants, Non-current | 0.00 | |
| Other non-current liabilities | ||
| Total of other non-current liabilities | ||
| Total non-current liabilities | 2,394.80 | |
| Current liabilities | ||
| Current financial liabilities | ||
| Borrowings, current | 12,138.60 | |
| Trade payables, current | ||
| (A) Total outstanding dues of micro enterprises and small enterprises | 2,086.70 | |
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 34,595.40 | |
| Total Trade payable | 36,682.10 | |
| Other current financial liabilities | ||
| 1 | Lease Liabilities | 413.20 |
| 2 | Other Financial Liabilities | 1,511.20 |
| Total of other current financial liabilities | 1,924.40 | |
| Total current financial liabilities | 50,745.10 | |
| Other current liabilities | 396.30 | |
| 1 | Other current liabilities | 396.30 |
| Total of other current liabilities | 396.30 | |
| Provisions, current | 390.30 | |
| Current tax liabilities (Net) | 587.70 | |
| Deferred government grants, Current | ||
| Total current liabilities | 52,119.40 | |
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | |
| Total liabilities | 54,514.20 | |
| Total equity and liabilites | 1,76,363.60 | |
| Disclosure of notes on assets and liabilities | ||
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-01-2026 | 01-04-2025 | |||||
| Date of end of reporting period | 31-03-2026 | 31-03-2026 | |||||
| Whether results are audited or unaudited | Audited | Audited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Remeasurements of the defined benefit plans | 21.50 | (6.60) |
| Total Amount of items that will not be reclassified to profit and loss | 21.50 | (6.60) | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 5.40 | (1.60) |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | ||
| 5 | Total Other comprehensive income | 16.10 | (5.00) |
| Particulars | Year ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|
| A | Date of start of reporting period | 01-04-2025 | ||||
| B | Date of end of reporting period | 31-03-2026 | ||||
| C | Whether results are audited or unaudited | Audited | ||||
| D | Nature of report standalone or consolidated | Standalone | ||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | 19,106.20 | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 1,213.10 | |||||
| Adjustments for decrease (increase) in inventories | (89.60) | |||||
| Adjustments for decrease (increase) in trade receivables, current | (17,248.30) | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0.00 | |||||
| Adjustments for decrease (increase) in other current assets | 0.00 | |||||
| Adjustments for decrease (increase) in other non-current assets | 0.00 | |||||
| Adjustments for other financial assets, non-current | 0.00 | |||||
| Adjustments for other financial assets, current | 0.00 | |||||
| Adjustments for other bank balances | 0.00 | |||||
| Adjustments for increase (decrease) in trade payables, current | 7,756.80 | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |||||
| Adjustments for increase (decrease) in other current liabilities | 0.00 | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 0.00 | |||||
| Adjustments for depreciation and amortisation expense | 3,093.30 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 0.00 | |||||
| Adjustments for provisions, current | 15.00 | |||||
| Adjustments for provisions, non-current | 0.00 | |||||
| Adjustments for other financial liabilities, current | 0.00 | |||||
| Adjustments for other financial liabilities, non-current | 0.00 | |||||
| Adjustments for unrealised foreign exchange losses gains | (425.70) | |||||
| Adjustments for dividend income | 17.50 | |||||
| Adjustments for interest income | 341.20 | |||||
| Adjustments for share-based payments | 140.00 | |||||
| Adjustments for fair value losses (gains) | 0.00 | |||||
| Adjustments for undistributed profits of associates | 0.00 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | (2,208.60) | |||||
| Other adjustments to reconcile profit (loss) | 0.00 | |||||
| Other adjustments for non-cash items | 32.50 | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Total adjustments for reconcile profit (loss) | (8,080.20) | |||||
| Net cash flows from (used in) operations | 11,026.00 | |||||
| Dividends received | 0.00 | |||||
| Interest paid | 0.00 | |||||
| Interest received | 0.00 | |||||
| Income taxes paid (refund) | 5,153.10 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) operating activities | 5,872.90 | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0.00 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 1,940.20 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 0.00 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | (1,097.00) | |||||
| Other cash receipts from sales of interests in joint ventures | 0.00 | |||||
| Other cash payments to acquire interests in joint ventures | 0.00 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Proceeds from sales of property, plant and equipment | 2,417.40 | |||||
| Purchase of property, plant and equipment | 11,874.20 | |||||
| Proceeds from sales of investment property | 0.00 | |||||
| Purchase of investment property | 0.00 | |||||
| Proceeds from sales of intangible assets | 0.00 | |||||
| Purchase of intangible assets | 0.00 | |||||
| Proceeds from sales of intangible assets under development | 0.00 | |||||
| Purchase of intangible assets under development | 0.00 | |||||
| Proceeds from sales of goodwill | 0.00 | |||||
| Purchase of goodwill | 0.00 | |||||
| Proceeds from biological assets other than bearer plants | 0.00 | |||||
| Purchase of biological assets other than bearer plants | 0.00 | |||||
| Proceeds from government grants | 0.00 | |||||
| Proceeds from sales of other long-term assets | 0.00 | |||||
| Purchase of other long-term assets | 0.00 | |||||
| Cash advances and loans made to other parties | 235.70 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 0.00 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Dividends received | 17.50 | |||||
| Interest received | 244.10 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 133.70 | |||||
| Net cash flows from (used in) investing activities | (10,140.40) | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |||||
| Payments from changes in ownership interests in subsidiaries | 0.00 | |||||
| Proceeds from issuing shares | 0.00 | |||||
| Proceeds from issuing other equity instruments | 83.30 | |||||
| Payments to acquire or redeem entity's shares | 0.00 | |||||
| Payments of other equity instruments | 0.00 | |||||
| Proceeds from exercise of stock options | 0.00 | |||||
| Proceeds from issuing debentures notes bonds etc | 0.00 | |||||
| Proceeds from borrowings | 9,663.30 | |||||
| Repayments of borrowings | 26.70 | |||||
| Payments of lease liabilities | 345.00 | |||||
| Dividends paid | 276.80 | |||||
| Interest paid | 1,185.20 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) financing activities | 7,912.90 | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 3,645.40 | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | (71.20) | |||||
| Net increase (decrease) in cash and cash equivalents | 3,574.20 | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 1,290.60 | |||||
| Cash and cash equivalents cash flow statement at end of period | 4,864.80 | |||||
| Whether results are audited or unaudited | Audited |
|---|---|
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | Walker Chandiok & Co LLP | Yes | 31-05-2028 | ||
|---|---|---|---|---|---|
Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) |
| Sr No. | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. | ||||||||||||||||||||||||
| Details of the party (listed entity/subsidiary) entering into the transaction | Details of the counterparty | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | Details of the loans, inter-corporate deposits, advances or investments | Notes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Opening balance | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment ) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | ||||||||||
| 1 | Rossari Biotech Limited | Sunil Chari | Key Managerial Personnel | Remuneration | As per the Companies Act, 2013 and Shareholders' Approval | 28.50 | 0.00 | 0.00 | |||||||||||||||||
| 2 | Rossari Biotech Limited | Edward Menezes | Key Managerial Personnel | Remuneration | As per the Companies Act, 2013 and Shareholders' Approval | 38.50 | 0.00 | 0.00 | |||||||||||||||||
| 3 | Rossari Biotech Limited | Mikhail Menezes | Relative of Director | Remuneration | As per the Companies Act, 2013 and Shareholders' Approval | 50.90 | 0.00 | 0.00 | |||||||||||||||||
| 4 | Rossari Biotech Limited | Yash Chari | Relative of Director | Remuneration | As per the Companies Act, 2013 and Shareholders' Approval | 17.70 | 0.00 | 0.00 | |||||||||||||||||
| 5 | Rossari Biotech Limited | Ketan Sablok | Key Managerial Personnel | Remuneration | As per the Companies Act, 2013 and Shareholders' Approval | 99.10 | 0.00 | 0.00 | |||||||||||||||||
| 6 | Rossari Biotech Limited | Parul Gupta | Key Managerial Personnel | Remuneration | As per the Companies Act, 2013 and Shareholders' Approval | 17.80 | 0.00 | 0.00 | |||||||||||||||||
| 7 | Rossari Biotech Limited | Rupesh Ruparelia | Key Managerial Personnel | Remuneration | As per the Companies Act, 2013 and Shareholders' Approval | 25.90 | 0.00 | 0.00 | |||||||||||||||||
| 8 | Rossari Biotech Limited | Aseem Dhru | Independent Director | Any other transaction | Sitting Fees | NA | 4.00 | 0.00 | 0.00 | ||||||||||||||||
| 9 | Rossari Biotech Limited | Gurudas Aras | Independent Director | Any other transaction | Sitting Fees | NA | 7.00 | 0.00 | 0.00 | ||||||||||||||||
| 10 | Rossari Biotech Limited | Aparna Sharma | Independent Director | Any other transaction | Sitting Fees | NA | 7.00 | 0.00 | 0.00 | ||||||||||||||||
| 11 | Rossari Biotech Limited | Esha Achan | Independent Director | Any other transaction | Sitting Fees | NA | 7.00 | 0.00 | 0.00 | ||||||||||||||||
| 12 | Rossari Biotech Limited | Buzil Rossari Private Limited | Wholly Owned Subsidiary Company | Sale of goods or services | 7,500.00 | NA | 1,913.70 | 7,294.40 | 8,022.90 | ||||||||||||||||
| 13 | Rossari Biotech Limited | Buzil Rossari Private Limited | Wholly Owned Subsidiary Company | Purchase of goods or services | 300.00 | NA | 8.90 | 9.80 | 2.30 | ||||||||||||||||
| 14 | Rossari Biotech Limited | Buzil Rossari Private Limited | Wholly Owned Subsidiary Company | Loan | 5,000.00 | NA | 0.00 | 2,400.00 | 2,400.00 | Loan | 8.00 | On Demand | Unsecured | General Business Requirement | |||||||||||
| 15 | Rossari Biotech Limited | Buzil Rossari Private Limited | Wholly Owned Subsidiary Company | Interest received | 5,000.00 | NA | 96.30 | 0.00 | 0.00 | ||||||||||||||||
| 16 | Rossari Biotech Limited | Buzil Rossari Private Limited | Wholly Owned Subsidiary Company | Any other transaction | Employee Cost - Recovery | 500.00 | NA | 67.70 | 0.00 | 0.00 | |||||||||||||||
| 17 | Rossari Biotech Limited | Buzil Rossari Private Limited | Wholly Owned Subsidiary Company | Any other transaction | Employee Cost - Reimbursement | 500.00 | NA | 3.10 | 0.00 | 0.00 | |||||||||||||||
| 18 | Rossari Biotech Limited | Buzil Rossari Private Limited | Wholly Owned Subsidiary Company | Any other transaction | Recovery of Expenses | 500.00 | NA | 50.50 | 0.00 | 0.00 | |||||||||||||||
| 19 | Rossari Biotech Limited | Rossari Consumer Products Private Limited | Wholly Owned Subsidiary Company | Sale of goods or services | 6,000.00 | NA | 1,653.10 | 1,999.90 | 3,160.90 | ||||||||||||||||
| 20 | Rossari Biotech Limited | Rossari Consumer Products Private Limited | Wholly Owned Subsidiary Company | Any other transaction | Employee Cost - Recovery | 500.00 | NA | 5.00 | 0.00 | 0.00 | |||||||||||||||
| 21 | Rossari Biotech Limited | Rossari Consumer Products Private Limited | Wholly Owned Subsidiary Company | Any other transaction | Recovery of Expenses | 500.00 | NA | 8.60 | 0.00 | 0.00 | |||||||||||||||
| 22 | Rossari Biotech Limited | Tristar Intermediates Private Limited | Wholly Owned Subsidiary Company | Sale of goods or services | 1,500.00 | NA | 189.30 | 410.40 | 1,012.90 | ||||||||||||||||
| 23 | Rossari Biotech Limited | Tristar Intermediates Private Limited | Wholly Owned Subsidiary Company | Any other transaction | Commission Income | 1,500.00 | NA | 95.00 | 0.00 | 0.00 | |||||||||||||||
| 24 | Rossari Biotech Limited | Tristar Intermediates Private Limited | Wholly Owned Subsidiary Company | Purchase of goods or services | 25,000.00 | NA | 10,383.30 | 7,798.90 | 10,408.50 | ||||||||||||||||
| 25 | Rossari Biotech Limited | Tristar Intermediates Private Limited | Wholly Owned Subsidiary Company | Any other transaction | Employee Cost - Recovery | 500.00 | NA | 210.90 | 0.00 | 0.00 | |||||||||||||||
| 26 | Rossari Biotech Limited | Tristar Intermediates Private Limited | Wholly Owned Subsidiary Company | Any other transaction | Recovery of Expenses | 500.00 | NA | 12.60 | 0.00 | 0.00 | |||||||||||||||
| 27 | Rossari Biotech Limited | Unitop Chemicals Private Limited | Subsidiary Company | Sale of goods or services | 28,800.00 | NA | 3,234.10 | 3,662.70 | 4,672.90 | ||||||||||||||||
| 28 | Rossari Biotech Limited | Unitop Chemicals Private Limited | Subsidiary Company | Any other transaction | Commission Income | 28,800.00 | NA | 464.70 | 0.00 | 0.00 | |||||||||||||||
| 29 | Rossari Biotech Limited | Unitop Chemicals Private Limited | Subsidiary Company | Sale of fixed assets | 500.00 | NA | 33.10 | 0.00 | 0.00 | ||||||||||||||||
| 30 | Rossari Biotech Limited | Unitop Chemicals Private Limited | Subsidiary Company | Purchase of goods or services | 70,000.00 | NA | 26,141.30 | 14,815.80 | 13,087.50 | ||||||||||||||||
| 31 | Rossari Biotech Limited | Unitop Chemicals Private Limited | Subsidiary Company | Any other transaction | Employee Cost - Recovery | 3,000.00 | NA | 730.90 | 0.00 | 0.00 | |||||||||||||||
| 32 | Rossari Biotech Limited | Unitop Chemicals Private Limited | Subsidiary Company | Any other transaction | Recovery of Expenses | 3,000.00 | NA | 62.50 | 0.00 | 0.00 | |||||||||||||||
| 33 | Rossari Biotech Limited | Romakk Chemicals Private Limited | Associate | Sale of goods or services | 600.00 | NA | 7.20 | 19.90 | 20.80 | ||||||||||||||||
| 34 | Rossari Biotech Limited | Romakk Chemicals Private Limited | Associate | Purchase of goods or services | 4,000.00 | NA | 1,266.00 | 695.40 | 901.90 | ||||||||||||||||
| 35 | Rossari Biotech Limited | Romakk Chemicals Private Limited | Associate | Any other transaction | Employee Cost - Recovery | 200.00 | NA | 17.70 | 0.00 | 0.00 | |||||||||||||||
| 36 | Rossari Biotech Limited | Romakk Chemicals Private Limited | Associate | Any other transaction | Recovery of Expenses | 200.00 | NA | 3.20 | 0.00 | 0.00 | |||||||||||||||
| 37 | Rossari Biotech Limited | K. K. Chempro (India) Private Limited | Related Party to Romakk Chemicals Private Limited (subsidiary company) | Any other transaction | Receivables Ac | NA | 0.00 | 0.10 | 0.10 | ||||||||||||||||
| 38 | Rossari Biotech Limited | K. K. Chempro (India) Private Limited | Related Party to Romakk Chemicals Private Limited (subsidiary company) | Purchase of goods or services | 900.00 | NA | 0.00 | 6.10 | 0.00 | ||||||||||||||||
| 39 | Rossari Biotech Limited | INSAI CHEMPLAST (Formerly known as K K CHEMICAL INDUSTRIES) | Related Party to Romakk Chemicals Private Limited (subsidiary company) | Any other transaction | Payable Account Debit Balance | NA | 0.00 | 0.50 | 0.50 | ||||||||||||||||
| 40 | Rossari Biotech Limited | McCoy Performance Silicones Private Limited | Related Party to Romakk Chemicals Private Limited (subsidiary company) | Any other transaction | Payable Account Debit Balance | NA | 0.00 | 0.10 | 0.10 | ||||||||||||||||
| 41 | Rossari Biotech Limited | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | Wholly Owned Subsidiary Company | Loan | 1,893.10 | NA | 0.00 | 1,060.50 | 1,175.90 | Loan | 10.0 | On Demand | Unsecured | General Business Requirement | |||||||||||
| 42 | Rossari Biotech Limited | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | Wholly Owned Subsidiary Company | Interest received | 189.30 | NA | 52.90 | 89.80 | 157.90 | ||||||||||||||||
| 43 | Rossari Biotech Limited | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | Wholly Owned Subsidiary Company | Any other transaction | Recovery of Expenses | 94.70 | NA | 1.90 | 19.90 | 23.40 | |||||||||||||||
| 44 | Rossari Biotech Limited | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | Wholly Owned Subsidiary Company | Any other transaction | Corporate Guarantee Given | 1,893.10 | NA | 0.00 | 1,347.90 | 1,490.80 | |||||||||||||||
| 45 | Rossari Biotech Limited | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | Wholly Owned Subsidiary Company | Any other transaction | Corporate Guarantee Commission Income | 18.90 | NA | 17.60 | 0.00 | 0.00 | |||||||||||||||
| 46 | Rossari Biotech Limited | Rossari Biotech Trading FZE | Step Down Wholly Owned Subsidiary | Sale of goods or services | 44,487.50 | NA | 7,507.40 | 992.10 | 3,786.80 | ||||||||||||||||
| 47 | Rossari Biotech Limited | Rossari Biotech Trading FZE | Step Down Wholly Owned Subsidiary | Any other transaction | Recovery of Expenses | 56.80 | NA | 9.20 | 0.00 | 0.00 | |||||||||||||||
| 48 | Rossari Biotech Limited | Rossari Biotech Trading FZE | Step Down Wholly Owned Subsidiary | Any other transaction | Corporate Guarantee Given | 7,572.30 | NA | 0.00 | 5,391.60 | 5,963.20 | |||||||||||||||
| 49 | Rossari Biotech Limited | Rossari Biotech Trading FZE | Step Down Wholly Owned Subsidiary | Any other transaction | Corporate Guarantee Commission Income | 75.70 | NA | 70.30 | 0.00 | 0.00 | |||||||||||||||
| 50 | Rossari Biotech Limited | Unistar Thai Company Limited | Step Down Wholly Owned Subsidiary | Sale of goods or services | 5,679.30 | NA | 234.90 | 38.30 | 291.70 | ||||||||||||||||
| 51 | Rossari Biotech Limited | Unistar Thai Company Limited | Step Down Wholly Owned Subsidiary | Purchase of goods or services | 3,312.90 | NA | 28.40 | 0.00 | 0.00 | ||||||||||||||||
| 52 | Rossari Biotech Limited | Unistar Thai Company Limited | Step Down Wholly Owned Subsidiary | Any other transaction | Recovery of Expenses | 94.70 | NA | 18.50 | 0.00 | 0.00 | |||||||||||||||
| 53 | Rossari Biotech Limited | Unistar Thai Company Limited | Step Down Wholly Owned Subsidiary | Any other transaction | Corporate Guarantee Given | 9,465.40 | NA | 0.00 | 6,739.50 | 7,454.00 | |||||||||||||||
| 54 | Rossari Biotech Limited | Unistar Thai Company Limited | Step Down Wholly Owned Subsidiary | Any other transaction | Corporate Guarantee Commission Income | 94.70 | NA | 87.90 | 0.00 | 0.00 | |||||||||||||||
| 55 | Rossari Biotech Limited | K K Chem India Private Limited | Related Party to Romakk Chemicals Private Limited (subsidiary company) | Purchase of goods or services | 500.00 | NA | 35.40 | 8.30 | 4.90 | ||||||||||||||||
| 56 | Rossari Biotech Limited | Rossari International Limited Company | Wholly Owned Subsidiary Company | Loan | 11,169.20 | NA | 235.70 | 0.00 | 250.30 | Loan | 7.300 | On Demand | Unsecured | General Business Requirement | |||||||||||
| 57 | Rossari Biotech Limited | Rossari International Limited Company | Wholly Owned Subsidiary Company | Interest received | 1,135.90 | NA | 7.20 | 0.00 | 7.70 | ||||||||||||||||
| 58 | Rossari Biotech Limited | Rossari International Limited Company | Wholly Owned Subsidiary Company | Any other transaction | Recovery of Expenses | 1,135.90 | NA | 77.70 | 0.00 | 77.70 | |||||||||||||||
| 59 | Rossari Biotech Limited | Rossari International Limited Company | Wholly Owned Subsidiary Company | Investment | NA | 1,940.00 | 0.00 | 0.00 | |||||||||||||||||
| 60 | Rossari Biotech Limited | Rossari Singapore PTE Limited | Wholly Owned Subsidiary Company | Investment | NA | 0.10 | 0.00 | 0.00 | |||||||||||||||||
| 61 | Unitop Chemicals Private Limited | Gurudas Aras | Independent Director | Any other transaction | Sitting Fees | NA | 1.00 | 0.00 | 0.00 | ||||||||||||||||
| 62 | Unitop Chemicals Private Limited | Aparna Sharma | Independent Director | Any other transaction | Sitting Fees | NA | 1.00 | 0.00 | 0.00 | ||||||||||||||||
| 63 | Unitop Chemicals Private Limited | Tristar Intermediates Private Limited | Fellow Subsidiary | Sale of goods or services | 3,500.00 | NA | 2,366.20 | 1,368.90 | 2,510.10 | ||||||||||||||||
| 64 | Unitop Chemicals Private Limited | Tristar Intermediates Private Limited | Fellow Subsidiary | Purchase of goods or services | 4,000.00 | NA | 1,033.50 | 921.60 | 754.30 | ||||||||||||||||
| 65 | Unitop Chemicals Private Limited | Buzil Rossari Private Limited | Fellow Subsidiary | Purchase of goods or services | 100.00 | NA | 0.10 | 5.40 | 5.50 | ||||||||||||||||
| 66 | Unitop Chemicals Private Limited | Buzil Rossari Private Limited | Fellow Subsidiary | Any other transaction | Reimbursement | 50.00 | NA | 12.50 | 0.00 | 0.00 | |||||||||||||||
| 67 | Unitop Chemicals Private Limited | Hextar Unitop SDN.BHD. | Joint Venture | Sale of goods or services | 600.00 | NA | 117.90 | 194.50 | 29.90 | ||||||||||||||||
| 68 | Unitop Chemicals Private Limited | Romakk Chemicals Private Limited | Associate of Holding Company | Sale of goods or services | 125.00 | NA | 18.90 | 9.40 | 0.00 | ||||||||||||||||
| 69 | Unitop Chemicals Private Limited | Romakk Chemicals Private Limited | Associate of Holding Company | Purchase of goods or services | 1,500.00 | NA | 62.00 | 311.10 | 0.00 | ||||||||||||||||
| 70 | Unitop Chemicals Private Limited | Glad Properties (India) Private Limited | Promoter Group Company | Any other transaction | Rent | 24.00 | NA | 11.80 | 11.70 | 2.20 | |||||||||||||||
| 71 | Tristar Intermediates Private Limited | Meher Castelino | Independent Director | Any other transaction | Sitting Fees | NA | 0.30 | 0.00 | 0.00 | ||||||||||||||||
| 72 | Tristar Intermediates Private Limited | Gurudas Aras | Independent Director | Any other transaction | Sitting Fees | NA | 0.50 | 0.00 | 0.00 | ||||||||||||||||
| 73 | Tristar Intermediates Private Limited | Buzil Rossari Private Limited | Fellow Subsidiary | Purchase of goods or services | NA | 0.10 | 1.90 | 1.90 | |||||||||||||||||
| 74 | Tristar Intermediates Private Limited | Buzil Rossari Private Limited | Fellow Subsidiary | Any other transaction | Reimbursement Expenses (Employee) | NA | 4.20 | 0.00 | 0.00 | ||||||||||||||||
| 75 | Tristar Intermediates Private Limited | Romakk Chemicals Private Limited | Fellow Subsidiary | Sale of goods or services | 125.00 | NA | 0.00 | 0.00 | 0.10 | ||||||||||||||||
| 76 | Buzil Rossari Private Limited | Rossari Consumer Products Private Limited | Fellow Subsidiary | Any other transaction | Employee Cost - Recovery | 50.00 | NA | 0.00 | 1.00 | 0.00 | |||||||||||||||
| 77 | Buzil Rossari Private Limited | Rockdude Impex Private Limited | Related Party of Fellow Subsidiary | Sale of goods or services | 10,000.00 | NA | 642.30 | 1,546.30 | 585.50 | ||||||||||||||||
| 78 | Buzil Rossari Private Limited | Rockdude Impex Private Limited | Related Party of Fellow Subsidiary | Purchase of goods or services | 10,000.00 | NA | 2,745.90 | (3,105.50) | (4,664.30) | ||||||||||||||||
| 79 | Romakk Chemicals Private Limited | Nitin Sethi | Key Managerial Personnel | Remuneration | As per the Companies Act, 2013 and Shareholders' Approval | 15.00 | 0.00 | 0.00 | |||||||||||||||||
| 80 | Romakk Chemicals Private Limited | Amit Malhotra | Key Managerial Personnel | Remuneration | As per the Companies Act, 2013 and Shareholders' Approval | 6.00 | 0.00 | 0.00 | |||||||||||||||||
| 81 | Romakk Chemicals Private Limited | Gurudas Aras | Independent Director | Any other transaction | Sitting Fees | NA | 1.30 | 0.00 | 0.00 | ||||||||||||||||
| 82 | Romakk Chemicals Private Limited | Esha Achan | Independent Director | Any other transaction | Sitting Fees | NA | 0.50 | 0.00 | 0.00 | ||||||||||||||||
| 83 | Romakk Chemicals Private Limited | Meher Castelino | Independent Director | Any other transaction | Sitting Fees | NA | 0.50 | 0.00 | 0.00 | ||||||||||||||||
| 84 | Romakk Chemicals Private Limited | K. K. Chempro (India) Private Limited | Enterprises on which Director or their relatives are able to exercise significant influence | Purchase of goods or services | 500.00 | NA | 0.00 | 2.00 | 0.00 | ||||||||||||||||
| 85 | Romakk Chemicals Private Limited | K K Chem India Private Limited | Enterprises on which Director or their relatives are able to exercise significant influence | Sale of goods or services | 10.00 | NA | 3.40 | 0.00 | 4.00 | ||||||||||||||||
| 86 | Romakk Chemicals Private Limited | K K Chem India Private Limited | Enterprises on which Director or their relatives are able to exercise significant influence | Purchase of goods or services | 500.00 | NA | 127.00 | 21.90 | 28.20 | ||||||||||||||||
| 87 | Romakk Chemicals Private Limited | K. K. Chempro (India) Private Limited | Enterprises on which Director or their relatives are able to exercise significant influence | Any other transaction | Rent | 12.00 | NA | 6.00 | 0.00 | 1.10 | |||||||||||||||
| 88 | Romakk Chemicals Private Limited | Nitin Sethi (HUF) | Enterprises on which Director or their relatives are able to exercise significant influence | Any other transaction | Rent | 9.00 | NA | 4.50 | 0.00 | 0.70 | |||||||||||||||
| 89 | Romakk Chemicals Private Limited | Sumant Agrawal (HUF) | Enterprises on which Director or their relatives are able to exercise significant influence | Any other transaction | Rent | 9.00 | NA | 4.50 | 0.00 | 0.80 | |||||||||||||||
| 90 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | Sunil Chari | Director | Remuneration | As per the Companies Act, 2013 | 54.90 | 0.00 | 0.00 | |||||||||||||||||
| 91 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | Yashika Chari | Relative of Director | Remuneration | As per the Companies Act, 2013 and Shareholders' Approval | 37.10 | 0.00 | 0.00 | |||||||||||||||||
| 92 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | Rupesh Ruparelia | Manager | Remuneration | As per the Companies Act, 2013 | 8.90 | 0.00 | 0.00 | |||||||||||||||||
| 93 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | Rossari Biotech Trading FZE | Wholly Owned Subsidiary Company | Loan | NA | (96.70) | 325.80 | 255.60 | Loan | 10.0 | On Demand | Unsecured | General Business Requirement | ||||||||||||
| 94 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | Rossari Biotech Trading FZE | Wholly Owned Subsidiary Company | Interest received | NA | 32.40 | 10.50 | 7.30 | |||||||||||||||||
| 95 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | Unistar Thai Company Limited | Wholly Owned Subsidiary Company | Loan | NA | (36.50) | 291.10 | 281.20 | Loan | 10.0 | On Demand | Unsecured | General Business Requirement | ||||||||||||
| 96 | Rossari Global FZCO (Formerly known as Rossari Global DMCC) | Unistar Thai Company Limited | Wholly Owned Subsidiary Company | Interest received | NA | 29.90 | 5.10 | 7.50 | |||||||||||||||||
| 97 | Rossari International Limited Company | Rupesh Ruparelia | Manager | Remuneration | As per the Companies Act, 2013 | 7.30 | 0.00 | 0.00 | |||||||||||||||||
| 98 | Rossari Biotech Trading FZE | Edward Menezes | Director | Remuneration | As per the Companies Act, 2013 | 42.80 | 0.00 | 0.00 | |||||||||||||||||
| 99 | Rossari Biotech Trading FZE | Yash Chari | Director | Remuneration | As per the Companies Act, 2013 | 34.80 | 0.00 | 0.00 | Textual Information(1) | ||||||||||||||||
| Total value of transaction during the reporting period | 64,589.00 | ||||||||||||||||||||||||
| Textual Information(1) | 1. The value of the related party transaction approved by the audit committee represents the value approved by audit committee of the respective company, as applicable. 2. Remuneration does not include stock options granted in accordance with the Rossari Employee Stock Option Plan- 2019, these options would vest after fulfillment of vesting conditions in accordance with the plan. Remuneration reported pertains to the amount paid during the period. 3. Transactions between members of the Group (between Rossari Biotech Limited and its subsidiary or between subsidiaries) are reported once. 4. The related transactions have been valued at the Average rate for the half year ended 31st March 2026. Further all the closing balances are valued at Closing rate as on 31st March 2026. (whereever necessary). 5.. For transactions between foreign subsidiaries, the conversion rate as on March 31, 2026 was applied. |
| Sr. No. | Particulars | Amount | Remarks |
| 1. | Loans / revolving facilities like cash credit from banks / financial institutions | ||
| A | Total amount outstanding as on date | 0.00 | |
|---|---|---|---|
| B | Of the total amount outstanding, amount of default as on date | 0.00 | |
| 2. | Unlisted debt securities i.e. NCDs and NCRPS | ||
| A | Total amount outstanding as on date | 0.00 | |
| B | Of the total amount outstanding, amount of default as on date | 0.00 | |
| 3. | Total financial indebtedness of the listed entity including short-term and long-term debt | 0.00 | |